PURPOSE: To evaluate the spectrum of scleritis from 2 tertiary eye care centers in Turkey. METHODS: Data from 114 patients with scleritis (82 female and 32 male; mean age, 48 +/- 17.7 years; age range, 4-87 years; 47 diffuse, 49 nodular, 7 necrotizing, and 11 posterior) who had undergone treatment between 1995 and 2006 were recorded. RESULTS: Mean follow-up duration was 16.9 months. Thirteen patients (12%) had bilateral ocular disease at presentation, and 21 patients (19%) developed bilateral ocular disease during follow-up. Decreased visual acuity was most common (60%) in posterior scleritis and least common (2%) in diffuse scleritis. Thirty-six patients (32%) had associated systemic disease, and in 13 patients (11%), scleritis was the presenting symptom of a systemic disease. CONCLUSIONS: Scleritis is a form of ocular inflammation frequently associated with systemic autoimmune disease and ocular complications. Close follow-up, systemic evaluation, and timely treatment are necessary in all patients with scleritis.
No takes yet. Share an insight, caveat, or question.
Erkanlı et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: